It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial
Gilead’s high profile STELLAR-4 study of its top late-stage NASH drug selonsertib has hit the finish line, and it’s starting out Phase III results with a big-time failure.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
